TTRX Company Profile and Key Details

Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 1 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $8.00. The high target offers -25.65% upside. The low target suggests -40.52% downside. The mean target is $8.50. This offers -36.8% upside. Turn Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended August 13, 2026, missed forecasts by 900.0%. The prior quarter beat by 250.0%. Over the last six quarters, Apple has recorded several small beats. These include 76.47% in March 31, 2026.

Our AI price prediction model suggests that Turn Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.43%, with price expected at $14.18 by September 28, 2026, within a range of $12.97 to $15.28 3-Month Outlook: Projected rise of 22.23%, reaching $16.44 by December 10, 2026, with a range of $16.30 to $16.57. 1-Year Outlook: Projected gain of 219.63%, with price at $42.99 by September 14, 2027, within a range of $42.91 to $43.12.

Turn Therapeutics Inc. (NASDAQ:TTRX) shares are up 17.26% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Turn Therapeutics Inc. trading at a premium to the broader market with a P/E of -46.13. Analyst sentiment is cautious, with the majority of ratings in Sell territory and a mean price target of $8.50, suggesting -36.8% downside. Our AI forecast model points to short-term strength (5.43% over two weeks), a medium-term rise (22.23% over three months), and a longer-term gain (219.63% over one year), with expected trading ranges indicating moderate volatility.

Turn Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.36. This means the shares are trading above this model’s fair value.

Turn Therapeutics Inc. (NASDAQ:TTRX) closed at $13.45 USD, gaining $0.76 (5.99%) from the previous close of $12.69. The stock is currently mid-range between its 52-week high and low $2.57 and $26.50. With a market capitalization of about $400.65 million, Turn Therapeutics Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.05). Key stats such as the average daily volume over the past year has been around 89.86 thousand shares, in line with its 52-week average. Headquartered in Westlake Village, CA, Turn Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Bradley E. Burnam, the company employs approximately 2 people and listed since October 08, 2025. Turn Therapeutics Inc., officially known as Global Health Solutions, Inc., is a pharmaceutical enterprise dedicated to developing treatments for conditions affecting the skin, nails, and eyes.

Turn Therapeutics Inc. trades at a P/E ratio of -46.13, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 582.97 reflecting a rich premium to book value. The P/FCF stands at -92.67, also below market averages. Compared to sector medians, Turn Therapeutics Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.